Literature DB >> 10204596

Trypanosoma cruzi in a low- to moderate-risk blood donor population: seroprevalence and possible congenital transmission.

D A Leiby1, M H Fucci, R J Stumpf.   

Abstract

BACKGROUND: Several recent studies documented the seroprevalence of Trypanosoma cruzi in blood donors at high risk for infection, but little information is available regarding donors with lower levels of risk. Thus, the present study was designed to measure the seroprevalence of T. cruzi in a donor population with a low to moderate risk for infection. STUDY DESIGN AND METHODS: During a 10-month period, donations from all allogeneic blood donors in the American Red Cross Southwest Region were tested for T. cruzi antibodies by enzyme immunoassay, and results were confirmed by radioimmunoprecipitation. Confirmed-seropositive donors were counseled and lookback investigations were initiated for those who were repeat donors.
RESULTS: A total of 100,089 donations were tested: 150 were repeatably reactive, and 3 (0.003%) were confirmed as positive for T. cruziantibodies. All three seropositive donors were from the Waco, TX, area, where the estimated seroprevalence rate was 1 in 7700. Two of these three donors reported no risk factors; both were born in the United States and had not traveled to an endemic area. Both had extensive familial histories of cardiac disease and complications.
CONCLUSION: Blood donors seropositive for T. cruzi are present in populations with low to moderate risk, albeit at lower rates. The presence of seropositive blood donors without the usual identifiable risk factors argues against the use of a geographic screening question and also suggests that other routes of transmission, including the congenital route, should be considered in efforts to increase blood safety.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10204596     DOI: 10.1046/j.1537-2995.1999.39399219290.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  13 in total

1.  Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme-linked immunosorbent assay kits.

Authors:  D A Leiby; S Wendel; D T Takaoka; R M Fachini; L C Oliveira; M A Tibbals
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

3.  Survey of obstetrician-gynecologists in the United States about Chagas disease.

Authors:  Jennifer R Verani; Susan P Montgomery; Jay Schulkin; Britta Anderson; Jeffrey L Jones
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

4.  2,3-diphenyl-1,4-naphthoquinone: a potential chemotherapeutic agent against Trypanosoma cruzi.

Authors:  Enrique I Ramos; Kristine M Garza; R L Krauth-Siegel; Julia Bader; Luiz E Martinez; Rosa A Maldonado
Journal:  J Parasitol       Date:  2009-04       Impact factor: 1.276

5.  Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV.

Authors:  Wesley C Van Voorhis; Lynn K Barrett; Richard T Eastman; Ryan Alfonso; Kent Dupuis
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 6.  Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysis.

Authors:  E J Howard; X Xiong; Y Carlier; S Sosa-Estani; P Buekens
Journal:  BJOG       Date:  2013-08-07       Impact factor: 6.531

7.  Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling.

Authors:  Momar Ndao; Terry W Spithill; Rebecca Caffrey; Hongshan Li; Vladimir N Podust; Regis Perichon; Cynthia Santamaria; Alberto Ache; Mark Duncan; Malcolm R Powell; Brian J Ward
Journal:  J Clin Microbiol       Date:  2010-01-13       Impact factor: 5.948

8.  Mother-to-child transmission of Chagas' disease in North America: why don't we do more?

Authors:  Pierre Buekens; Olivia Almendares; Yves Carlier; Eric Dumonteil; Mark Eberhard; Rubi Gamboa-Leon; Mark James; Nicolas Padilla; Dawn Wesson; Xu Xiong
Journal:  Matern Child Health J       Date:  2007-06-30

Review 9.  Heart Failure Secondary to Chagas Disease: an Emerging Problem in Non-endemic Areas.

Authors:  Mahmoud Traina; Sheba Meymandi; Jason S Bradfield
Journal:  Curr Heart Fail Rep       Date:  2016-12

Review 10.  Historical Perspectives on the Epidemiology of Human Chagas Disease in Texas and Recommendations for Enhanced Understanding of Clinical Chagas Disease in the Southern United States.

Authors:  Melissa N Garcia; Laila Woc-Colburn; David Aguilar; Peter J Hotez; Kristy O Murray
Journal:  PLoS Negl Trop Dis       Date:  2015-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.